ALNY

Alnylam Pharmaceuticals, Inc. Press Releases

$97.92
*  
4.40
4.7%
Get ALNY Alerts
*Delayed - data as of Dec. 26, 2014  -  Find a broker to begin trading ALNY now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Alnylam Announces Planned Departure of Chief Business Officer, Laurence Reid, Ph.D.
12/19/2014 8:00:00 AM - Business Wire
▼-1.50 % Price Change since this news event. The Volume Ratio is 2.05.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam Elects Michael W. Bonney to Its Board of Directors
12/18/2014 8:00:00 AM - Business Wire
▲1.52 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Quarterly Changes to the NXTQ Index
12/15/2014 7:20:00 AM - GlobeNewswire


Alnylam Introduces Pipeline Growth Strategy for RNAi Therapeutics in Three Strategic Therapeutic Areas, or “STArs”
12/12/2014 7:00:00 AM - Business Wire
▼-2.08 % Price Change since this news event. The Volume Ratio is 0.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam Initiates ENDEAVOUR Phase 3 Clinical Trial with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis
12/11/2014 4:00:00 PM - Business Wire
▼-2.26 % Price Change since this news event. The Volume Ratio is 0.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia
12/11/2014 8:00:00 AM - Business Wire
▼-3.05 % Price Change since this news event. The Volume Ratio is 0.89.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam Reports Positive Initial Results for ALN-AT3, an Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders, from Ongoing Phase 1 Trial
12/8/2014 9:15:00 PM - Business Wire
▼-7.99 % Price Change since this news event. The Volume Ratio is 1.36.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam Files Clinical Trial Application (CTA) for ALN-CC5, an RNAi Therapeutic Targeting Complement C5 in Development for the Treatment of Complement-Mediated Diseases
12/7/2014 10:10:00 AM - Business Wire
▼-1.33 % Price Change since this news event. The Volume Ratio is 2.03.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam to Webcast R&D Day
12/4/2014 4:00:00 PM - Business Wire
▼-2.15 % Price Change since this news event. The Volume Ratio is 1.33.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam to Webcast Presentation at the Oppenheimer 25th Annual Healthcare Conference
12/3/2014 4:00:00 PM - Business Wire
▼-2.00 % Price Change since this news event. The Volume Ratio is 1.15.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


American Express Global Business Travel Appoints Elyes Mrad to Run EMEA Operations
12/1/2014 9:00:00 AM - Business Wire


New Paper in Journal of the American Chemical Society Documents Pioneering Discovery of GalNAc-Conjugated siRNA by Alnylam Scientists
12/1/2014 9:00:00 AM - Business Wire
▼-2.62 % Price Change since this news event. The Volume Ratio is 1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam to Webcast Presentations at Upcoming Investor Conferences
11/25/2014 4:00:00 PM - Business Wire


Alnylam Presents New Pre-Clinical Data on RNAi Therapeutic Programs for Cardio-Metabolic Diseases at American Heart Association Scientific Sessions 2014
11/17/2014 5:00:00 PM - Business Wire


Alnylam Announces Positive Initial Phase 2 Data with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis, with up to 98.2% Knockdown of Serum TTR in Patients
11/14/2014 6:00:00 AM - Business Wire
▼-1.03 % Price Change since this news event. The Volume Ratio is 1.6.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV for the Treatment of Chronic Hepatitis Delta Virus (HDV) Infection and ALN-PDL for the Treatment of Chronic Liver Infections
11/11/2014 8:00:00 AM - Business Wire
▼-1.27 % Price Change since this news event. The Volume Ratio is 0.61.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam to Webcast Presentation at the Credit Suisse 2014 Healthcare Conference
11/6/2014 4:00:00 PM - Business Wire
▲5.39 % Price Change since this news event. The Volume Ratio is 1.09.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam Pharmaceuticals Reports Third Quarter 2014 Financial Results and Highlights Recent Period Progress
11/5/2014 4:00:00 PM - Business Wire
▲11.26 % Price Change since this news event. The Volume Ratio is 1.47.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam Completes Phase 2 Enrollment and Initiates Open-Label Extension (OLE) Study with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis
11/5/2014 8:00:00 AM - Business Wire
▲10.02 % Price Change since this news event. The Volume Ratio is 0.77.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam to Webcast Presentation at the Nomura Biotechnology Conference
10/30/2014 4:00:00 PM - Business Wire
▲3.38 % Price Change since this news event. The Volume Ratio is 1.34.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam to Webcast Conference Call Discussing Third Quarter 2014 Financial Results
10/29/2014 4:00:00 PM - Business Wire
▲6.98 % Price Change since this news event. The Volume Ratio is 0.73.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam Appoints Pushkal Garg, M.D., Senior Vice President, Clinical Development
10/29/2014 8:00:00 AM - Business Wire
▲6.43 % Price Change since this news event. The Volume Ratio is 1.35.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam and The Medicines Company Announce Filing of a Clinical Trial Application to Initiate a Phase 1 Study for ALN-PCSsc, an Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia
10/28/2014 8:00:00 AM - Business Wire
▲5.39 % Price Change since this news event. The Volume Ratio is 1.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam Launches Alnylam Assist™, Dedicated to Providing Support to Patients, Families, and Caregivers in Certain Genetic Diseases
10/20/2014 8:00:00 AM - Business Wire
▲13.86 % Price Change since this news event. The Volume Ratio is 0.38.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam Presents New Clinical and Pre-Clinical Data on RNAi Therapeutics at 10th Oligonucleotide Therapeutics Society (OTS) Meeting
10/14/2014 8:00:00 AM - Business Wire
▲12.42 % Price Change since this news event. The Volume Ratio is 0.96.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day